{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:20:10Z","timestamp":1793974810944,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Department of Science, University, and Knowledge Society of the Government of Arag\u00f3n (Spain) (Research Group B58_23R)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50334-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:07:27Z","timestamp":1777025247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Modulatory effects of valproic acid and UGT polymorphisms on norclozapine plasma levels in clozapine-treated patients with schizophrenia"],"prefix":"10.1038","volume":"16","author":[{"given":"Estela","family":"Sang\u00fcesa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cirujeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Ribate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Bel\u00e9n","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"50334_CR1","doi-asserted-by":"crossref","unstructured":"Kauffman, F.C. Conjugation\u2014Deconjugation Reactions in Drug Metabolism and Toxicity. Handbook of Experimental Pharmacology, vol 112. Springer, Berlin, Heidelberg (1994).","DOI":"10.1007\/978-3-642-78429-3"},{"key":"50334_CR2","doi-asserted-by":"publisher","first-page":"1088458","DOI":"10.3389\/fonc.2022.1088458","volume":"12","author":"W Liu","year":"2023","unstructured":"Liu, W., Li, J., Zhao, R., Lu, Y. & Huang, P. The Uridine diphosphate (UDP)-glycosyltransferases (UGTs) superfamily: the role in tumor cell metabolism. Front. Oncol. 12, 1088458 (2023).","journal-title":"Front. Oncol."},{"key":"50334_CR3","first-page":"487","volume":"286","author":"WE Evans","year":"1999","unstructured":"Evans, W. E., Relling, M. V. & Pharmacogenomics Translating functional genomics into rational therapeutics. Science (1979) 286, 487\u2013491 (1999).","journal-title":"Sci. (1979)"},{"key":"50334_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.phrs.2017.05.001","volume":"121","author":"N Yang","year":"2017","unstructured":"Yang, N., Sun, R., Liao, X., Aa, J. & Wang, G. UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine. Pharmacol. Res. 121, 169\u2013183 (2017).","journal-title":"Pharmacol. Res."},{"key":"50334_CR5","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3109\/00498254.2011.563327","volume":"41","author":"S Kaivosaari","year":"2011","unstructured":"Kaivosaari, S., Finel, M. & Koskinen, M. N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 41, 652\u2013669 (2011).","journal-title":"Xenobiotica"},{"key":"50334_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/978-1-0716-1554-6_12","volume":"2342","author":"J Zhou","year":"2021","unstructured":"Zhou, J., Argikar, U. A. & Miners, J. O. Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs). Methods Mol. Biol. 2342, 301\u2013338 (2021).","journal-title":"Methods Mol. Biol."},{"key":"50334_CR7","doi-asserted-by":"publisher","first-page":"225472","DOI":"10.3389\/fphar.2016.00388","volume":"7","author":"R Fujiwara","year":"2016","unstructured":"Fujiwara, R., Yokoi, T. & Nakajima, M. Structure and protein-protein interactions of human UDP-glucuronosyltransferases. Front. Pharmacol. 7, 225472 (2016).","journal-title":"Front. Pharmacol."},{"key":"50334_CR8","unstructured":"Green, M. D. & Tephly, T. R. Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins: 1996 ASPET N-Glucuronidation of xenobiotics symposium. Drug Metab. Dispos. 26, 860\u2013867 (1998)."},{"key":"50334_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpba.2017.07.037","volume":"145","author":"D Lu","year":"2017","unstructured":"Lu, D., Xie, Q. & Wu, B. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: Assay optimization and substrate identification. J. Pharm. Biomed. Anal. 145, 692\u2013703 (2017).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"50334_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1124\/dmd.113.051565","volume":"41","author":"Y Kato","year":"2013","unstructured":"Kato, Y. et al. Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab. Dispos. 41, 1389\u20131397 (2013).","journal-title":"Drug Metab. Dispos."},{"key":"50334_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/FPC.0b013e3283602e75","volume":"23","author":"M Dobrinas","year":"2013","unstructured":"Dobrinas, M., Cornuz, J. & Eap, C. B. Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. Pharmacogenet. Genomics. 23, 286\u2013292 (2013).","journal-title":"Pharmacogenet Genomics"},{"key":"50334_CR12","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jcpt.12118","volume":"39","author":"L Song","year":"2014","unstructured":"Song, L., Du, Q., Jiang, X. & Wang, L. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J. Clin. Pharm. Ther. 39, 204\u2013209 (2014).","journal-title":"J. Clin. Pharm. Ther."},{"key":"50334_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1176\/appi.ajp.2019.18050589","volume":"176","author":"AF Pardi\u00f1as","year":"2019","unstructured":"Pardi\u00f1as, A. F. et al. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. Am. J. Psychiatry. 176, 477\u2013486 (2019).","journal-title":"Am. J. Psychiatry"},{"key":"50334_CR14","doi-asserted-by":"crossref","unstructured":"Smith, R. L. et al. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients-a genome-wide association study adjusting for smoking habits. Transl. Psychiatry 10, (2020).","DOI":"10.1038\/s41398-020-01061-4"},{"key":"50334_CR15","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1124\/dmd.104.002576","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori, A., Maruo, Y., Iwai, M., Sato, H. & Takeuchi, Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab. Dispos. 33, 672\u2013675 (2005).","journal-title":"Drug Metab. Dispos."},{"key":"50334_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","volume":"22","author":"KK Erickson-Ridout","year":"2012","unstructured":"Erickson-Ridout, K. K., Sun, D. & Lazarus, P. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet. Genomics. 22, 561\u2013576 (2012).","journal-title":"Pharmacogenet Genomics"},{"key":"50334_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/1389200223666220201152953","volume":"23","author":"RL Smith","year":"2022","unstructured":"Smith, R. L. et al. Effects of a novel UGT2B haplotype and UGT1A4*3 allele variants on glucuronidation of clozapine in vivo. Curr. Drug Metab. 23, 66\u201372 (2022).","journal-title":"Curr. Drug Metab."},{"key":"50334_CR18","doi-asserted-by":"crossref","unstructured":"Ozdemir, F. et al. The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients. Toxicol Appl. Pharmacol 495, (2025).","DOI":"10.1016\/j.taap.2024.117219"},{"key":"50334_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/2045125311405566","volume":"1","author":"S Varma","year":"2011","unstructured":"Varma, S., Bishara, D., Besag, F. M. C. & Taylor, D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther. Adv. Psychopharmacol. 1, 47\u201366 (2011).","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"50334_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/FTD.0000000000000619","volume":"41","author":"RL Smith","year":"2019","unstructured":"Smith, R. L., Kylles\u00f8, L., Haslemo, T., Andreassen, O. A. & Molden, E. Reduction in N -desmethylclozapine level is determined by daily dose but not serum concentration of valproic acid - indications of a presystemic interaction mechanism. Ther. Drug Monit. 41, 503\u2013508 (2019).","journal-title":"Ther. Drug Monit."},{"key":"50334_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/JCP.0000000000001923","volume":"44","author":"RJ Flanagan","year":"2024","unstructured":"Flanagan, R. J., Obee, S. J., Kim, A. H. M. & Every-Palmer, S. Effect of valproate coprescription on clozapine pharmacokinetics in clinical practice. J. Clin. Psychopharmacol. 44, 561\u2013569 (2024).","journal-title":"J. Clin. Psychopharmacol."},{"key":"50334_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/JCP.0000000000001507","volume":"42","author":"RL Smith","year":"2022","unstructured":"Smith, R. L. et al. Effect of valproic acid on the metabolic spectrum of clozapine in patients with schizophrenia. J. Clin. Psychopharmacol. 42, 43\u201350 (2022).","journal-title":"J. Clin. Psychopharmacol."},{"key":"50334_CR23","doi-asserted-by":"publisher","unstructured":"Smith, R. L. et al. Correlation between serum concentrations of n-desmethylclozapine and granulocyte levels in patients with schizophrenia: A retrospective observational study. https:\/\/doi.org\/10.1007\/s40263-017-0469-1.","DOI":"10.1007\/s40263-017-0469-1"},{"key":"50334_CR24","doi-asserted-by":"publisher","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","volume":"76","author":"N Meyer","year":"2015","unstructured":"Meyer, N. et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. J. Clin. Psychiatry. 76, e1410\u2013e1416 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"50334_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","volume":"195","author":"S Malik","year":"2018","unstructured":"Malik, S. et al. Sodium valproate and clozapine induced neutropenia: A case control study using register data. Schizophr Res. 195, 267\u2013273 (2018).","journal-title":"Schizophr Res."},{"key":"50334_CR26","doi-asserted-by":"publisher","unstructured":"Yang, C. C., Wang, X. Y., Chou, P. H. et al. Valproate-related neutropenia and lithium-related leukocytosis in patients treated with clozapine: a retrospective cohort study. BMC Psychiatry 23, 170 (2023). https:\/\/doi.org\/10.1186\/s12888-023-04659-2.","DOI":"10.1186\/s12888-023-04659-2"},{"key":"50334_CR27","doi-asserted-by":"publisher","unstructured":"Hiemke, C. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51, 9\u201362 (2018). https:\/\/doi.org\/10.1055\/s-0043-116492","DOI":"10.1055\/s-0043-116492"},{"key":"50334_CR28","doi-asserted-by":"publisher","unstructured":"Patsalos, P. N. & ILAE Commission on Therapeutic Strategies. &. Antiepileptic drugs - Best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring. Epilepsia 49, 1239\u20131276 (2008). https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x.","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"50334_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos, P. N., Spencer, E. P. & Berry, D. J. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther. Drug Monit. 40, 526\u2013548. (2018). https:\/\/doi.org\/10.1097\/FTD.0000000000000546.","journal-title":"Ther. Drug Monit."},{"key":"50334_CR30","unstructured":"Practice guideline for the treatment of patients with bipolar disorder (revision) - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/11958165\/."},{"key":"50334_CR31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/15622975.2018.1439595","volume":"19","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis, G. et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians*. World J. Biol. Psychiatry. 19, 162\u2013174. (2018). https:\/\/doi.org\/10.1080\/15622975.2018.1439595.","journal-title":"World J. Biol. Psychiatry"},{"key":"50334_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1254\/jphs.FPE04007X","volume":"97","author":"J Hermida","year":"2005","unstructured":"Hermida, J. & Tutor, J. C. A theoretical method for normalizing total serum valproic acid concentration in hypoalbuminemic patients. J. Pharmacol. Sci. 97, 489\u2013493 (2005).","journal-title":"J. Pharmacol. Sci."},{"key":"50334_CR33","doi-asserted-by":"crossref","unstructured":"Dor\u00e9, M. I., Juan, H. S., Frenette, A. E. & Williamson, D. Clinical importance of monitoring unbound valproic acid concentration in patients with hypoalbuminemia. Pharmacotherapy 37, 900\u2013907 (2017).","DOI":"10.1002\/phar.1965"},{"key":"50334_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","volume":"66","author":"R Ghotbi","year":"2010","unstructured":"Ghotbi, R. et al. Carriers of the UGT1A4 142T\u2009>\u2009G gene variant are predisposed to reduced olanzapine exposure\u2013an impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol. 66, 465\u2013474 (2010).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"50334_CR35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/hep.20131","volume":"39","author":"U Ehmer","year":"2004","unstructured":"Ehmer, U. et al. Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 39, 970\u2013977 (2004).","journal-title":"Hepatology"},{"key":"50334_CR36","unstructured":"Dyer, S.C. et al. Ensembl 2025. Nucleic Acids Res. 6, 53 D948-D957 (2025).  https:\/\/www.ensembl.org\/index.html"},{"key":"50334_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/JCP.0000000000000877","volume":"38","author":"L Hommers","year":"2018","unstructured":"Hommers, L. et al. Comedication of Valproic Acid Is Associated with Increased Metabolism of Clozapine. J. Clin. Psychopharmacol. 38, 188\u2013192 (2018).","journal-title":"J. Clin. Psychopharmacol."},{"key":"50334_CR38","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00228-023-03569-2","volume":"79","author":"B Pani\u0107","year":"2023","unstructured":"Pani\u0107, B. et al. Association of clozapine and norclozapine levels with patient and therapy characteristics-focus on interaction with valproic acid. Eur. J. Clin. Pharmacol. 79, 1557\u20131564 (2023).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"50334_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.schres.2023.10.003","volume":"268","author":"H Verdoux","year":"2024","unstructured":"Verdoux, H., Quiles, C. & de Leon, J. Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations. Schizophr. Res. 268, 243\u2013251 (2024).","journal-title":"Schizophr Res."},{"key":"50334_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FTD.0000000000001177","volume":"46","author":"BM Wollmann","year":"2024","unstructured":"Wollmann, B. M., Haugen, A. G., Smith, R. L. & Molden, E. Novel identification of cysteinyl derivatives of toxic clozapine nitrenium ions and the effect of valproic acid on metabolite formation: A study using reprocessed high-resolution mass spectra of analyzed therapeutic drug monitoring samples. Ther. Drug Monit. 46, 265\u2013269 (2024).","journal-title":"Ther. Drug Monit."},{"key":"50334_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/FPC.0b013e328348c76b","volume":"21","author":"KK Erickson-Ridout","year":"2011","unstructured":"Erickson-Ridout, K. K., Zhu, J. & Lazarus, P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet. Genom. 21, 539\u2013551 (2011).","journal-title":"Pharmacogenet Genomics"},{"key":"50334_CR42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1124\/dmd.107.019406","volume":"36","author":"G Chen","year":"2008","unstructured":"Chen, G., Dellinger, R. W., Sun, D., Spratt, T. E. & Lazarus, P. Glucuronidation of Tobacco-Specific Nitrosamines by UGT2B10. Drug Metab. Dispos. 36, 824 (2008).","journal-title":"Drug Metab. Dispos."},{"key":"50334_CR43","doi-asserted-by":"publisher","first-page":"9024","DOI":"10.1158\/0008-5472.CAN-07-2245","volume":"67","author":"G Chen","year":"2007","unstructured":"Chen, G., Blevins-Primeau, A. S., Dellinger, R. W., Muscat, J. E. & Lazarus, P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp\u2009>\u2009Tyr) polymorphism. Cancer Res. 67, 9024\u20139029 (2007).","journal-title":"Cancer Res."},{"key":"50334_CR44","doi-asserted-by":"publisher","first-page":"e70938","DOI":"10.1371\/journal.pone.0070938","volume":"8","author":"AZX Zhu","year":"2013","unstructured":"Zhu, A. Z. X. et al. Variation in Trans-3\u2032-Hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS One 8, e70938 (2013).","journal-title":"PLoS One"},{"key":"50334_CR45","doi-asserted-by":"crossref","unstructured":"Sang\u00fcesa, E. et al. Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? Chem. Biol. Interact. 364, (2022).","DOI":"10.1016\/j.cbi.2022.110042"},{"key":"50334_CR46","doi-asserted-by":"crossref","unstructured":"Tang, L. W. T., Lapham, K. & Goosen, T. C. UGT2B10 is the major UDP-glucuronosyltransferase 2B isoform involved in the metabolism of lamotrigine and is implicated in the drug-drug interaction with valproic acid. AAPS J. 26, (2024).","DOI":"10.1208\/s12248-024-00978-8"},{"key":"50334_CR47","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eurpsy.2004.09.007","volume":"19","author":"MJ Imbarlina","year":"2004","unstructured":"Imbarlina, M. J. et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur. Psychiatry 19, 506\u2013509 (2004).","journal-title":"Eur. Psychiatry"},{"key":"50334_CR48","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1046\/j.1440-1614.2001.0911f.x","volume":"35","author":"C Pantelis","year":"2001","unstructured":"Pantelis, C. & Adesanya, A. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust N Z. J. Psychiatry 35, 544\u2013545 (2001).","journal-title":"Aust N Z. J. Psychiatry"},{"key":"50334_CR49","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/S0924-9338(02)00659-4","volume":"17","author":"R Madeb","year":"2002","unstructured":"Madeb, R., Hirschmann, S., Kurs, R., Turkie, A. & Modai, I. Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur. Psychiatry 17, 238\u2013239 (2002).","journal-title":"Eur. Psychiatry"},{"key":"50334_CR50","doi-asserted-by":"publisher","first-page":"2050313X2110197","DOI":"10.1177\/2050313X211019791","volume":"9","author":"MI Jakobsen","year":"2021","unstructured":"Jakobsen, M. I., Gr\u00f8nborg, H., Hansen, H. V. & Fink-Jensen, A. Clozapine-associated neutropenia following augmentation with sodium valproate. SAGE Open. Med. Case Rep. 9, 2050313X211019791 (2021).","journal-title":"SAGE Open. Med. Case Rep."},{"key":"50334_CR51","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.taap.2006.01.008","volume":"214","author":"Z Husain","year":"2006","unstructured":"Husain, Z. et al. Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol. Appl. Pharmacol. 214, 326\u2013334 (2006).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"50334_CR52","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.jcp.0000177668.42640.fe","volume":"25","author":"K Fehsel","year":"2005","unstructured":"Fehsel, K. et al. Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J. Clin. Psychopharmacol. 25, 419\u2013426 (2005).","journal-title":"J. Clin. Psychopharmacol."},{"key":"50334_CR53","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41537-023-00404-6","volume":"9","author":"SK Lock","year":"2023","unstructured":"Lock, S. K. et al. Mediation and longitudinal analysis to interpret the association between clozapine pharmacokinetics, pharmacogenomics, and absolute neutrophil count. Schizophrenia 9, 74 (2023).","journal-title":"Schizophrenia"},{"key":"50334_CR54","doi-asserted-by":"publisher","first-page":"658734","DOI":"10.3389\/fphar.2021.658734","volume":"12","author":"IR Willcocks","year":"2021","unstructured":"Willcocks, I. R. et al. Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant Schizophrenia. Front. Pharmacol. 12, 658734 (2021).","journal-title":"Front. Pharmacol."},{"key":"50334_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.pmedr.2016.08.009","volume":"4","author":"T Higuchi","year":"2016","unstructured":"Higuchi, T. et al. Current cigarette smoking is a reversible cause of elevated white blood cell count: Cross-sectional and longitudinal studies. Prev. Med. Rep. 4, 417\u2013422 (2016).","journal-title":"Prev. Med. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50334-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50334-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50334-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T23:33:28Z","timestamp":1781739208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50334-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50334"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50334-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki 1964 and its subsequent revisions (\n                      \n                      [accessed March 26th, 2018]) and approved by the Regional Ethics Committee of Arag\u00f3n (CEIC-A) (Acta N\u00ba 22\/2022, C.I. PI17\/0041). All participants provided written informed consent to participate. Data are published only in aggregate, in accordance with the information collected and accepted by the Regional Ethics Committee for consent to participate; therefore, consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"18950"}}